Stock Analysis

Beijing Scitop Bio-tech Third Quarter 2024 Earnings: EPS: CN¥0.099 (vs CN¥0.12 in 3Q 2023)

SZSE:300858
Source: Shutterstock

Beijing Scitop Bio-tech (SZSE:300858) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥80.7m (up 4.7% from 3Q 2023).
  • Net income: CN¥27.7m (down 13% from 3Q 2023).
  • Profit margin: 34% (down from 41% in 3Q 2023). The decrease in margin was driven by higher expenses.
  • EPS: CN¥0.099 (down from CN¥0.12 in 3Q 2023).
earnings-and-revenue-growth
SZSE:300858 Earnings and Revenue Growth October 31st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beijing Scitop Bio-tech Earnings Insights

Looking ahead, revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Food industry in China.

Performance of the Chinese Food industry.

The company's shares are down 1.7% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Beijing Scitop Bio-tech that you need to take into consideration.

Valuation is complex, but we're here to simplify it.

Discover if Beijing Scitop Bio-tech might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.